{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age+Related+Macular+Degeneration&page=22",
    "query": {
      "condition": "Age Related Macular Degeneration",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 913,
    "total_pages": 92,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age+Related+Macular+Degeneration&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age+Related+Macular+Degeneration&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T01:17:48.134Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01922128",
      "title": "Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nonexudative Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "MC-1101, Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MacuCLEAR, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-09",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 1,
      "location_summary": "Artesia, California",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01922128"
    },
    {
      "nct_id": "NCT00511706",
      "title": "Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Age-Related Maculopathy"
      ],
      "interventions": [
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sham",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 243,
      "start_date": "2007-11-01",
      "completion_date": "2009-03-01",
      "has_results": true,
      "last_update_posted_date": "2019-04-25",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 1,
      "location_summary": "Boynton Beach, Florida",
      "locations": [
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511706"
    },
    {
      "nct_id": "NCT00089830",
      "title": "A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat \"Wet\" Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "MSI-1256F (Squalamine Lactate)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genaera Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2004-08",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2007-11-28",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 1,
      "location_summary": "Plymouth Meeting, Pennsylvania",
      "locations": [
        {
          "city": "Plymouth Meeting",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089830"
    },
    {
      "nct_id": "NCT05110209",
      "title": "Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "OTHER"
        },
        {
          "name": "Ranibizumab",
          "type": "OTHER"
        },
        {
          "name": "Bevacizumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 331541,
      "start_date": "2020-07-15",
      "completion_date": "2020-11-20",
      "has_results": false,
      "last_update_posted_date": "2021-12-21",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05110209"
    },
    {
      "nct_id": "NCT03022292",
      "title": "The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Aflibercept Ophthalmic",
          "type": "DRUG"
        },
        {
          "name": "optovue angiovue",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2017-03-30",
      "completion_date": "2020-08-31",
      "has_results": true,
      "last_update_posted_date": "2022-01-06",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03022292"
    },
    {
      "nct_id": "NCT02827071",
      "title": "Ocular Imaging Study Using Advanced OCT",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinal Vascular Disorder",
        "Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "115 Years",
        "sex": "ALL",
        "summary": "18 Years to 115 Years"
      },
      "enrollment_count": 150,
      "start_date": "2016-07",
      "completion_date": "2021-12-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02827071"
    },
    {
      "nct_id": "NCT07064759",
      "title": "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "4D-150 IVT (3E10 vg/eye)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "4D Molecular Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2025-07-22",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 60,
      "location_summary": "Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07064759"
    },
    {
      "nct_id": "NCT00089765",
      "title": "Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Von Hippel-Lindau Syndrome"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2004-08-10",
      "completion_date": "2007-08-15",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089765"
    },
    {
      "nct_id": "NCT01940900",
      "title": "A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "E10030",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "E10030 sham intravitreal injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 627,
      "start_date": "2013-08",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2024-10-30",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 49,
      "location_summary": "Tucson, Arizona • Fresno, California • La Jolla, California + 43 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01940900"
    },
    {
      "nct_id": "NCT05147701",
      "title": "Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Eye Diseases",
        "Retinitis Pigmentosa",
        "Diabetic Retinopathy",
        "Macular Degeneration",
        "Traumatic Optic Neuropathy",
        "Optic Atrophy"
      ],
      "interventions": [
        {
          "name": "cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The Foundation for Orthopaedics and Regenerative Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2022-02-01",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-21T01:17:48.134Z",
      "location_count": 1,
      "location_summary": "Naples, Florida",
      "locations": [
        {
          "city": "Naples",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05147701"
    }
  ]
}